Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults
Sponsor: Serum Institute of India Pvt. Ltd.
Summary
The primary purpose of this study is to test a new experimental recombinant Poliomyelitis vaccine (rPV) in comparison to the commercially available inactivated poliovirus vaccine. The design of the study is double-blinded, randomised and active controlled. The active controlled product is considered the commercially available vaccine (IPOL).
Official title: A Phase 1, Double-blinded, Randomised, Active Controlled, Clinical Trial to Assess the Reactogenicity, Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2026-07
Completion Date
2027-03
Last Updated
2026-07-07
Healthy Volunteers
Yes
Conditions
Interventions
Recombinant Poliomyelitis Vaccine (rPV)
Recombinant Poliomyelitis Vaccine (VLP) is manufactured by Serum Institute of India Pvt. Ltd.
Inactivated Poliomyelitis Vaccine (IPOL)
IPOL (inactivated poliovirus vaccine) is a marketed Sanofi
Locations (1)
Doherty Clinical Trials Limited
East Melbourne, Victoria, Australia